Fibrocell Science (FCSC) Reports Q2 Loss of $1.03

Fibrocell Science (NASDAQ: FCSC) reported Q2 EPS of ($1.03), versus ($0.42) reported last year.

“During the second quarter of 2018, we attained important milestones that continue to advance the development of our gene therapy candidates for rare and devastating conditions affecting the skin and connective tissue,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “In May, we reported on interim results on the adult patients in the Phase 1 portion of our Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The data continued to show positive trends in safety, wound healing and pharmacology. Furthermore, we continue to progress the Phase 2 portion of the trial, including dosing our first patient and enrolling three pediatric patients.”

“Our FCX-013 gene therapy program for the treatment of moderate to severe localized scleroderma also made notable progress this quarter. The U.S. Food and Drug Administration (FDA) allowed our Investigational New Drug application earlier this year, and in August, we initiated the first investigator site for clinical enrollment for our open label, single arm Phase 1/2 clinical trial,” said Mr. Maslowski.

For earnings history and earnings-related data on Fibrocell Science (FCSC) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• CDW to acquire data and AI firm Lovelytics for $525 million
• Broadcom (AVGO) Tops Q3 EPS by 11c, Offers Guidance